PsA Forum: Tailored Approaches to Psoriatic Arthritis

• Multi-site virtual Hub and Spoke meeting
• Virtual hub will run pre-recorded presentations and run by the overall meeting Chair
• Ten to twelve spokes will be led by a designated KEE who is a ‘rising star’ in their field, in partnership with an Amgen country representative
• Two of the four evenings will contain a high level of audience interaction, facilitated by country affiliates

Goals:

• Describe how patients with moderate/oligoarticular PsA may have limited joint involvement but still exhibit a substantial burden of disease, which can impact their quality of life
• Recognize the heterogeneous nature of PsA, and describe how disease manifestations and comorbidities can contribute to a complex, individual burden of disease
• Highlight the importance of accurate assessment of disease severity in patients with moderate/oligoarticular PsA to enable early clinical intervention and appropriate clinical decision-making
• Outline the need for a tailored approach to the management and treatment of patients with PsA, where shared decision-making between patients and HCPs ensures that treatment decisions and goals are individualized and patient-focused